Dyne Therapeutics, Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. Dyne is a clinical-stage biotechnology company developing muscle-disease therapeutics using its FORCE platform. It has no products for sale and has generated no revenue.
Financial performance and position
| Metric | Q2 2022 / June 30, 2022 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $46.7 million Q2; $74.9 million first half | $23.9 million Q2; $42.5 million first half in 2021 |
| General and administrative expense | $6.1 million Q2; $13.6 million first half | $6.3 million Q2; $12.8 million first half in 2021 |
| Total operating expenses | $52.8 million Q2; $88.5 million first half | $30.2 million Q2; $55.3 million first half in 2021 |
| Net loss | $52.3 million Q2; $87.9 million first half | $30.0 million Q2; $54.9 million first half in 2021 |
| Net loss per share | $1.01 Q2; $1.70 first half | $0.58 Q2; $1.09 first half in 2021 |
| Cash, cash equivalents and marketable securities | $291.8 million | $376.6 million at Dec. 31, 2021 |
| Operating cash flow | $(81.6) million first half | $(64.5) million first half in 2021 |
| Total liabilities | $53.0 million | $57.5 million at Dec. 31, 2021 |
Cash and cash equivalents were $136.0 million and marketable securities were $155.9 million at June 30. Marketable securities were largely short-term; $148.4 million matured within one year. The balance sheet reports lease liabilities, accounts payable and accrued liabilities; it does not show a separate debt balance. No gross-profit margin is meaningful because Dyne had no revenue. Interest income was $0.4 million for Q2 and $0.7 million for the first half.
Changes versus prior comparable periods
- Q2 operating expenses increased $22.6 million year over year, primarily from higher R&D spending. External manufacturing and research costs rose $18.2 million in Q2, mainly reflecting manufacturing-process development, IND-enabling studies and clinical-trial start-up.
- First-half operating expenses increased $33.2 million year over year, and net loss widened by $33.0 million. First-half R&D expense increased $32.4 million.
- Cash, cash equivalents and marketable securities declined $84.8 million from year-end 2021. First-half operating cash use rose to $81.6 million from $64.5 million in 2021. First-half 2021 financing cash flow included $157.2 million of net proceeds from a follow-on offering; 2022 financing cash flow was $0.1 million, primarily option exercises.
- Q2 G&A expense was slightly lower year over year, partly due to a reduction in stock-based compensation; first-half G&A expense increased modestly.
Outlook, commentary and risks
- Management estimates existing cash, cash equivalents and marketable securities will fund operating expenses and capital needs into the second half of 2024, and expects liquidity to support proof-of-concept data readouts in multiple programs. These estimates depend on assumptions and could prove inaccurate.
- Management expects significant ongoing losses and rising expenses as programs advance; revenue from product sales is not expected for several years, if ever. Additional funding will be needed, with potential dilution, restrictive financing terms, or the need to delay or reduce programs if financing is unavailable.
- At the time of the filing, Dyne expected to begin dosing patients in Phase 1/2 multiple-ascending-dose trials of DYNE-101 for DM1 and DYNE-251 for DMD in mid-2022, and expected to submit an IND for DYNE-301 for FSHD in the second half of 2022. The filing reports FDA clearance of the DYNE-251 IND in July 2022, following a clinical hold and requests for additional information. DYNE-101 had received New Zealand trial-application clearance.
- Key risks include early-stage, unproven programs and platform; clinical, regulatory and enrollment uncertainty; reliance on third-party research and manufacturing; single-source suppliers for key components; intellectual-property and competition risks; and possible pandemic-related disruption. Dyne reported no material business disruption from COVID-19 to date but said future effects were uncertain.
- In June, modifications to the CEO’s equity awards reduced Q2 stock-based compensation expense by $0.9 million in total. Performance conditions on specified options and RSUs were achieved in July 2022, resulting in vesting after quarter-end.
- Management concluded disclosure controls were effective at the reasonable-assurance level as of June 30, 2022; no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- Whether the planned DYNE-101 and DYNE-251 trial dosing began on schedule, and the timing and content of initial clinical data readouts.
- Whether the expected second-half 2022 DYNE-301 IND submission occurred, and any subsequent regulatory updates.
- Whether the stated cash runway into the second half of 2024 remains supported by spending, clinical progress and financing assumptions.
- How R&D spending, cash burn and marketable-security balances evolve as clinical trials advance.
- Whether manufacturing capacity, supplier concentration, clinical execution or regulatory requirements create delays or additional costs.